In Figure 5 on page 1145, the numbers of patients in the CEBPA+/GATA2+ and CEBPA+/CSF3R+ molecular cohorts are reversed. In Figure 5A and C, the curves should be labeled as 23 patients with CEBPA+/GATA2+ and 13 patients with CEBPA+/CSF3R+. In Figure 5B, the curves should be labeled as 20 patients with CEBPA+/GATA2+ and 13 patients with CEBPA+/CSF3R+. The correct numbers of patients were used for analysis. The corrected Figure 5 is shown below.
Outcomes of CEBPA-mutant patients according to co-occurring CSF3R and GATA2 mutational status. (A) EFS of dual CEBPA+/CSF3R+ mutant patients compared with those with dual CEBPA+/GATA2+ and those with a CEBPA+ mutation and neither CSF3R nor GATA2; (B) RR of dual CEBPA+/CSF3R+ mutant patients compared with dual CEBPA+/GATA2+ and patients with a CEBPA+ mutation and neither CSF3R nor GATA2; (C) OS of dual CEBPA+/CSF3R+ mutant patients compared with dual CEBPA+/GATA2+ and patients with a CEBPA+ mutation and neither CSF3R nor GATA2.
Outcomes of CEBPA-mutant patients according to co-occurring CSF3R and GATA2 mutational status. (A) EFS of dual CEBPA+/CSF3R+ mutant patients compared with those with dual CEBPA+/GATA2+ and those with a CEBPA+ mutation and neither CSF3R nor GATA2; (B) RR of dual CEBPA+/CSF3R+ mutant patients compared with dual CEBPA+/GATA2+ and patients with a CEBPA+ mutation and neither CSF3R nor GATA2; (C) OS of dual CEBPA+/CSF3R+ mutant patients compared with dual CEBPA+/GATA2+ and patients with a CEBPA+ mutation and neither CSF3R nor GATA2.
The errors have been corrected in the online version of the article.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal